CMS delays requirement for drugmakers to offer multiple best prices for Medicaid value-based deals – FierceHealthcare

The Biden administration has delayed for six months the implementation of a Trump-era rule aimed at incentivizing the use of value-based drug price agreements in Medicaid.

The Centers for Medicare & Medicaid Services (CMS) released a proposed rule Wednesday that delays implementation of a requirement for manufacturers to report multiple best prices for a drug covered under Medicaid if the drugmaker is participating in a value-based purchasing arrangement.

The original version of the regulation, finalized on Dec. 31, 2020, implemented the requirement on Jan. 1, 2022, but the Biden administration wants to delay the deadline to July 1, 2022.

The reason for the delay is to give CMS, states and drugmakers more time to implement the “complex system changes necessary to implement the new best price and [value-based purchasing] program,” the proposed rule said.

The delay also will ensure resources are not diverted from the fight against COVID-19.

CMS said in the rule that more time is needed, especially “given the current need to devote resources to the public health emergency relating to COVID-19 that has been in effect and will likely remain in effect through 2021.”

RELATED: In a win for PBMs, Biden administration delays rebate rule

Drugmakers that participate in Medicaid must report to the federal government their “best price” for brand-name products, which is the amount a wholesaler, retailer or provider pays for it.

Manufacturers have claimed that the “best price” requirement has been a detriment to entering value-based purchasing arrangements for prescription drugs, a model that ties reimbursement of a drug